Shareholder Alert: Ademi LLP investigates whether EQRx, Inc. has obtained a Fair Price in its transaction with Revolution Medicines

MILWAUKEE, Aug. 2, 2023 /PRNewswire/ -- Ademi LLP is investigating EQRx (Nasdaq: EQRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Revolution Medicines. 

Click here to learn how to join the action https://www.ademilaw.com/case/eqrx-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

In the transaction, EQRx stockholders are expected to receive the number of shares of Revolution Medicines common stock equal to the sum of 7,692,308 Revolution Medicines shares (determined as $200 million divided by $26.00 per share) plus a number of shares equal to $870 million divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines share price measured in close proximity to the stockholder vote. The transaction agreement unreasonably limits competing transactions for EQRx by imposing a significant penalty if EQRx accepts a competing bid. EQRx insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of EQRx's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own EQRx common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/eqrx-inc.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP